PPBP [4-phenyl-1-(4-phenylbutyl) piperidine] decreases brain injury after transient focal ischemia in rats

Stroke. 1996 Nov;27(11):2120-3. doi: 10.1161/01.str.27.11.2120.

Abstract

Background and purpose: We tested the hypothesis that intravenous administration of the potent sigma-receptor ligand 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) during transient focal ischemia would decrease postischemic brain infarction volume in rats.

Methods: Rats underwent intravascular focal ischemia for 2 hours followed by 22 hours of reperfusion. Halothane anesthesia was used only during initiation and cessation of ischemia. Rats received saline (n = 10) or 1 mumol/kg per hour PPBP (n = 10) by continuous intravenous infusion starting 1 hour after the initiation of ischemia and continuing through 22 hours of reperfusion.

Results: There was no difference between groups in blood pressure, arterial blood gas values, and body temperature. Triphenyltetrazolium-determined infarction volume of ipsilateral cerebral cortex (saline, 39 +/- 6%; PPBP, 21 +/- 7% of ipsilateral hemisphere; mean +/- SEM) and striatum (saline, 68 +/- 6%; PPBP, 33 +/- 8% of ipsilateral striatum) was smaller in rats treated with PPBP than in rats treated with saline.

Conclusions: These data indicate that sigma-receptors may play an important role in the mechanism of injury both in cortex and striatum after 2 hours of transient focal ischemia in rats. Because PPBP afforded protection when administered at the end of ischemia and during reperfusion, sigma-receptors may influence the progression of injury in ischemic border regions.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Cerebral Infarction / etiology
  • Cerebral Infarction / metabolism
  • Cerebral Infarction / pathology
  • Cerebral Infarction / prevention & control*
  • Disease Models, Animal
  • Haloperidol / administration & dosage
  • Haloperidol / analogs & derivatives*
  • Haloperidol / therapeutic use
  • Infusions, Intravenous
  • Ischemic Attack, Transient / complications
  • Ischemic Attack, Transient / drug therapy*
  • Ischemic Attack, Transient / metabolism
  • Ischemic Attack, Transient / pathology
  • Male
  • Neuroprotective Agents / administration & dosage
  • Neuroprotective Agents / therapeutic use*
  • Rats
  • Receptors, sigma / drug effects
  • Time Factors
  • Treatment Outcome

Substances

  • Neuroprotective Agents
  • Receptors, sigma
  • 4-phenyl-1-(4-phenylbutyl)piperidine
  • Haloperidol